1. Kintz P, Samyn N. Use of alternative specimens: drugs of abuse in saliva and doping agents in hair. Ther Drug Monit. 2002;24:239–46. [PubMed] [Google Scholar]
2. Marquet P. Progress of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Ther Drug Monit. 2002;24:255–76. [PubMed] [Google Scholar]
3. Maurer HH. Liquid chromatography-mass spectrometry in forensic and clinical toxicology. J Chromatogr B Biomed Sci Appl. 1998;713:3–25. [PubMed] [Google Scholar]
4. Van Bocxlaer JF, Clauwaert KM, Lambert WE, Deforce DL, Van den Eeckhout EG, De Leenheer AP. Liquid chromatography-mass spectrometry in forensic toxicology. Mass Spectrom Rev. 2000;19:165–214. [PubMed] [Google Scholar]
5. Choo RE, Huestis MA. Oral fluid as a diagnostic tool. Clin Chem Lab Med. 2004;42:1273–87. [PubMed] [Google Scholar]
6. Caplan YH, Goldberger BA. Alternative specimens for workplace drug testing. J Anal Toxicol. 2001;25:396–9. [PubMed] [Google Scholar]
7. Walsh JM, de Gier JJ, Christopherson AS, Verstraete AG. Drugs and driving. Traffic Inj Prev. 2004;5:241–53. [PubMed] [Google Scholar]
8. Kadehjian L. Legal issues in oral fluid testing. Forensic Sci Int. 2005;150:151–60. [PubMed] [Google Scholar]
9. Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. 2004;26:200–5. [PubMed] [Google Scholar]
10. Drummer OH. Review: Pharmaco*kinetics of illicit drugs in oral fluid. Forensic Sci Int. 2005;150:133–42. [PubMed] [Google Scholar]
11. Aps JK, Martens LC. Review: The physiology of saliva and transfer of drugs into saliva. Forensic Sci Int. 2005;150:119–31. [PubMed] [Google Scholar]
12. O'Neal CL, Crouch DJ, Rollins DE, Fatah AA. The effects of collection methods on oral fluid codeine concentrations. J Anal Toxicol. 2000;24:536–42. [PubMed] [Google Scholar]
13. Crouch DJ. Oral fluid collection: the neglected variable in oral fluid testing. Forensic Sci Int. 2005;150:165–73. [PubMed] [Google Scholar]
14. Schepers RJ, Oyler JM, Joseph RE, Jr, Cone EJ, Moolchan ET, Huestis MA. Methamphetamine and amphetamine pharmaco*kinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem. 2003;49:121–32. [PubMed] [Google Scholar]
15. Kato K, Hillsgrove M, Weinhold L, Gorelick DA, Darwin WD, Cone EJ. Cocaine and metabolite excretion in saliva under stimulated and nonstimulated conditions. J Anal Toxicol. 1993;17:338–41. [PubMed] [Google Scholar]
16. Wong RC, Tran M, Tung JK. Oral fluid drug tests: effects of adulterants and foodstuffs. Forensic Sci Int. 2005;150:175–80. [PubMed] [Google Scholar]
17. Maseda C, Hama K, f*ckui Y, Matsubara K, Takahashi S, Akane A. Detection of delta 9-THC in saliva by capillary GC/ECD after marihuana smoking. Forensic Sci Int. 1986;32:259–66. [PubMed] [Google Scholar]
18. Chu M, Wells DL, King RG, Farrar J, Drummer OH. The effect of blood in the oral cavity on breath alcohol analysis. J Clin Forensic Med. 1998;5:114–8. [PubMed] [Google Scholar]
19. Teixeira H, Proenca P, Verstraete A, Corte-Real F, Vieira DN. Analysis of Delta9-tetrahydrocannabinol in oral fluid samples using solid-phase extraction and high-performance liquid chromatography-electrospray ionization mass spectrometry. Forensic Sci Int. 2005;150:205–11. [PubMed] [Google Scholar]
20. Dickson SJ, Park A, Nolan SL, et al. The recovery of drugs from oral fluid collection devices. Forensic Sci Int 2006;In Press. [PubMed]
21. Moore C, Vincent M, Rana S, Coulter C, Agrawal A, Soares J. Stability of Delta(9)-tetrahydrocannabinol (THC) in oral fluid using the Quantisal(TM) collection device. Forensic Sci Int Epub 2006 Jan 16 ahead of print. [PubMed]
22. Verstraete AG. Oral fluid testing for driving under the influence of drugs: history, recent progress and remaining challenges. Forensic Sci Int. 2005;150:143– 50. [PubMed] [Google Scholar]
23. Verstraete AG, Pierce A. Workplace drug testing in Europe. Forensic Sci Int. 2001;121:2–6. [PubMed] [Google Scholar]
24. George S. A snapshot of workplace drug testing in the UK. Occup Med (Lond) 2005;55:69–71. [PubMed] [Google Scholar]
25. Cone EJ, Jenkins AJ. Saliva Drug Analysis. In: Wong SHY, Sunshine I, eds. Handbook of Analytical Therapeutic Drug Monitoring and Toxicology. Roca Baton, Florida: CRC Press, 1997, pp303–33.
26. Cone EJ, Hillsgrove M, Darwin WD. Simultaneous measurement of cocaine, cocaethylene, their metabolites, and "crack" pyrolysis products by gas chromatographymass spectrometry. Clin Chem. 1994;40:1299–305. [PubMed] [Google Scholar]
27. Jenkins AJ, Oyler JM, Cone EJ. Comparison of heroin and cocaine concentrations in saliva with concentrations in blood and plasma. J Anal Toxicol. 1995;19:359–74. [PubMed] [Google Scholar]
28. Guidelines for testing drugs under international control in hair, sweat and saliva. Vienna, Austria: United Nations, 1998.
29. Jones AW. Inter- and intra-individual variations in the saliva/blood alcohol ratio during ethanol metabolism in man. Clin Chem. 1979;25:1394–8. [PubMed] [Google Scholar]
30. Haeckel R, Peiffer U. Comparison of ethanol concentration in saliva and blood from police controlled Clin Biochem Rev Vol 27 August 2006 I 155 Oral Fluid Drugs persons. Blutalkohol. 1992;29:342–9. [PubMed] [Google Scholar]
31. Jones AW. Measuring ethanol in saliva with the QED enzymatic test device: comparison of results with blood- and breath-alcohol concentrations. J Anal Toxicol. 1995;19:169–74. [PubMed] [Google Scholar]
32. Menkes DB, Howard RC, Spears GF, Cairns ER. Salivary THC following cannabis smoking correlates with subjective intoxication and heart rate. Psychopharmacology (Berl) 1991;103:277–9. [PubMed] [Google Scholar]
33. Huestis MA, Cone EJ. Relationship of delta-9- tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis. J Anal Toxicol. 2004;28:394–9. [PubMed] [Google Scholar]
34. O'Neal CL, Crouch DJ, Rollins DE, Fatah A, Cheever ML. Correlation of saliva codeine concentrations with plasma concentrations after oral codeine administration. J Anal Toxicol. 1999;23:452–9. [PubMed] [Google Scholar]
35. Kim I, Barnes AJ, Oyler JM, et al. Plasma and oral fluid pharmaco*kinetics and pharmacodynamics after oral codeine administration. Clin Chem. 2002;48:1486–96. [PubMed] [Google Scholar]
36. Mendelson J, Upton RA, Everhart ET, Jacob P, 3rd, Jones RT. Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997;37:31–7. [PubMed] [Google Scholar]
37. Nath RP, Upton RA, Everhart ET, et al. Buprenorphine pharmaco*kinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol. 1999;39:619–23. [PubMed] [Google Scholar]
38. Cone EJ, Dickerson SL, Darwin WD, Fudala P, Johnson RE. Elevated drug saliva levels suggest a "depot-like" effect in subjects treated with sublingual buprenorphine. NIDA Res Monogr. 1990;105:569. [PubMed] [Google Scholar]
39. Curvall M, Elwin CE, Kazemi-Vala E, Warholm C, Enzell CR. The pharmaco*kinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. Eur J Clin Pharmacol. 1990;38:281–7. [PubMed] [Google Scholar]
40. Curvall M, Vala EK, Enzell CR, Wahren J. Simulation and evaluation of nicotine intake during passive smoking: cotinine measurements in body fluids of nonsmokers given intravenous infusions of nicotine. Clin Pharmacol Ther. 1990;47:42–9. [PubMed] [Google Scholar]
41. Giles HG, Miller R, Macleod SM, Sellers EM. Diazepam and N-desmethyldiazepam in saliva of hospital inpatients. J Clin Pharmacol. 1980;20:71–6. [PubMed] [Google Scholar]
42. DiGregorio GJ, Piraino AJ, Ruch E. Diazepam concentrations in parotid saliva, mixed saliva, and plasma. Clin Pharmacol Ther. 1978;24:720–5. [PubMed] [Google Scholar]
43. de Gier JJ, 't Hart BJ, Nelemans FA, Bergman H. Psychom*otor performance and real driving performance of outpatients receiving diazepam. Psychopharmacology (Berl) 1981;73:340–4. [PubMed] [Google Scholar]
44. Concheiro M, Villain M, Bouchet S, Ludes B, Lopez- Rivadulla M, Kintz P. Windows of detection of tetrazepam in urine, oral fluid, beard, and hair, with a special focus on drug-facilitated crimes. Ther Drug Monit. 2005;27:565–70. [PubMed] [Google Scholar]
45. Samyn N, De Boeck G, Cirimele V, Verstraete A, Kintz P. Detection of flunitrazepam and 7- aminoflunitrazepam in oral fluid after controlled administration of rohypnol. J Anal Toxicol. 2002;26:211–5. [PubMed] [Google Scholar]
46. Hart BJ, Wilting J, de Gier JJ. The stability of benzodiazepines in saliva. Methods Find Exp Clin Pharmacol. 1988;10:21–6. [PubMed] [Google Scholar]
47. Ritschel WA, Parab PV, Denson DD, Coyle DE, Gregg RV. Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects. J Clin Pharmacol. 1987;27:647–53. [PubMed] [Google Scholar]
48. Matin SB, Wan SH, Knight JB. Quantitative determination of enantiomeric compounds. I-- Simultaneous measurement of the optical isomers of amphetamine in human plasma and saliva using chemical ionization mass spectrometry. Biomed Mass Spectrom. 1977;4:118–21. [PubMed] [Google Scholar]
49. Chen ZR, Bochner F, Somogyi A. Pharmaco*kinetics of pholcodine in healthy volunteers: single and chronic dosing studies. Br J Clin Pharmacol. 1988;26:445–53. [PMC free article] [PubMed] [Google Scholar]
50. Tracqui A, Ludes B. HPLC-MS for the determination of sildenafil citrate (Viagra) in biological fluid s. Application to the salivary excretion of sildenafil after oral intake. J Anal Toxicol. 2003;27:88–94. [PubMed] [Google Scholar]
51. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva. An update. Clin Pharmaco*kinet. 1992;23:365–79. [PubMed] [Google Scholar]
52. Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmaco*kinet. 1999;36:453–70. [PubMed] [Google Scholar]
53. Vasudev A, Tripathi KD, Puri V. Correlation of serum and salivary carbamazepine concentration in epileptic patients: implications for therapeutic drug monitoring. Neurol India. 2002;50:60–2. [PubMed] [Google Scholar]
54. Miles MV, Tang PH, Glauser TA, et al. Topiramate concentration in saliva: an alternative to serum monitoring. Pediatr Neurol. 2003;29:143–7. [PubMed] [Google Scholar]
55. Moolchan ET, Umbricht A, Epstein D. Therapeutic drug monitoring in methadone maintenance: choosing a matrix. J Addict Dis. 2001;20:55–73. [PubMed] [Google Scholar]
56. Sagawa K, Mohri K, Shimada S, Shimizu M, Muramatsu J. Disopyramide concentrations in human plasma and saliva: comparison of disopyramide concentrations in saliva and plasma unbound concentrations. Eur J Clin Pharmacol. 1997;52:65–9. [PubMed] [Google Scholar]
57. Mortier KA, Renard V, Verstraete AG, Van Gussem A, Van Belle S, Lambert WE. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of docetaxel and pacl*taxel in human plasma and oral fluid. Anal Chem 2005;77:4677–83. 156 I Clin Biochem Rev Vol 27 August 2006 Drummer O [PubMed]
58. Spielberg F, Critchlow C, Vittinghoff E, et al. Home collection for frequent HIV testing: acceptability of oral fluid s, dried blood spots and telephone results. HIV Early Detection Study Group. AIDS. 2000;14:1819–28. [PubMed] [Google Scholar]
59. Soldin SJ, Rakhmanina NY, Spiegel HM, Sever JL. Therapeutic drug monitoring for patients with HIV infection: Children's National Medical Center, Washington DC experience. Ther Drug Monit. 2004;26:107–9. [PubMed] [Google Scholar]
60. Gallagher P, Leitch MM, Massey AE, McAllister Williams RH, Young AH. Assessing cortisol and dehydroepiandrosterone (DHEA) in saliva: effects of collection method. J Psychopharmacol 2006 Jan 9 ahead of print. Jan 9;[Epub ahead of print] [PubMed]
61. Mylonas PG, Makri M, Georgopoulos NA, et al. Adequacy of saliva 17-hydroxyprogesterone determination using various collection methods. Steroids. 2006;71:273–6. [PubMed] [Google Scholar]
62. Kintz P, Cirimele V, Ludes B. Codeine testing in sweat and saliva with the Drugwipe. Int J Legal Med. 1998;111:82–4. [PubMed] [Google Scholar]
63. Samyn N, van Haeren C. On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users. Int J Legal Med. 2000;113:150–4. [PubMed] [Google Scholar]
64. Grönholm M, Lillsunde P. A comparison between onsite immunoassay drug-testing devices and laboratory results. Forensic Sci Int. 2001;121:37–46. [PubMed] [Google Scholar]
65. Kolbrich EA, Kim I, Barnes AJ, et al. Cozart RapiScan Oral Fluid Drug Testing System: an evaluation of sensitivity, specificity, and efficiency for cocaine detection compared with ELISA and GC-MS following controlled cocaine administration. J Anal Toxicol. 2003;27:407–11. [PubMed] [Google Scholar]
66. Samyn N, De Boeck G, Verstraete AG. The use of oral fluid and sweat wipes for the detection of drugs of abuse in drivers. J Forensic Sci. 2002;47:1380–7. [PubMed] [Google Scholar]
67. Pichini S, Navarro M, Farre M, et al. On-site testing of 3,4-methylenedioxymethamphetamine (ecstasy) in saliva with Drugwipe and Drugread: a controlled study in recreational users. Clin Chem. 2002;48:174–6. [PubMed] [Google Scholar]
68. Laloup M, Tilman G, Maes V, et al. Validation of an ELISA-based screening assay for the detection of amphetamine, MDMA and MDA in blood and oral fluid. Forensic Sci Int. 2005;153:29–37. [PubMed] [Google Scholar]
69. Kupiec T, DeCicco L, Spiehler V, Sneed G, Kemp P. Choice of an ELISA assay for screening postmortem blood for amphetamine and/or methamphetamine. J Anal Toxicol. 2002;26:513–8. [PubMed] [Google Scholar]
70. De Giovanni N, Fucci N, Scarlata S, Donzelli G. Buprenorphine detection in biological samples. Clin Chem Lab Med. 2005;43:1377–9. [PubMed] [Google Scholar]
71. Kim I, Barnes AJ, Schepers R, et al. Sensitivity and specificity of the Cozart microplate EIA cocaine oral fluid at proposed screening and confirmation cutoffs. Clin Chem. 2003;49:1498–503. [PubMed] [Google Scholar]
72. Lachenmeier K, Musshoff F, Madea B. Determination of opiates and cocaine in hair using automated enzyme immunoassay screening methodologies followed by gas chromatographic-mass spectrometric (GC-MS) confirmation. Forensic Sci Int. 2006;159:189–99. [PubMed] [Google Scholar]
73. Cooper G, Wilson L, Reid C, Baldwin D, Hand C, Spieher V. Validation of the Cozart microplate EIA for cocaine and metabolites in oral fluid. J Anal Toxicol. 2004;28:498–503. [PubMed] [Google Scholar]
74. Cooper G, Wilson L, Reid C, Baldwin D, Hand C, Spiehler V. Comparison of GC-MS and EIA results for the analysis of methadone in oral fluid. J Forensic Sci. 2005;50:928–32. [PubMed] [Google Scholar]
75. Kacinko SL, Barnes AJ, Kim I, et al. Performance characteristics of the Cozart RapiScan Oral Fluid Drug Testing System for opiates in comparison to ELISA and GC/MS following controlled codeine administration. Forensic Sci Int. 2004;141:41–8. [PubMed] [Google Scholar]
76. Barnes AJ, Kim I, Schepers R, et al. Sensitivity, specificity, and efficiency in detecting opiates in oral fluid with the Cozart Opiate Microplate EIA and GCMS following controlled codeine administration. J Anal Toxicol. 2003;27:402–7. [PubMed] [Google Scholar]
77. Niedbala RS, Kardos KW, Fritch DF, et al. Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol. 2001;25:289–303. [PubMed] [Google Scholar]
78. Kemp P, Sneed G, Kupiec T, Spiehler V. Validation of a microtiter plate ELISA for screening of postmortem blood for opiates and benzodiazepines. J Anal Toxicol. 2002;26:504–12. [PubMed] [Google Scholar]
79. Allen KR, Azad R, Field HP, Blake DK. Replacement of immunoassay by LC tandem mass spectrometry for the routine measurement of drugs of abuse in oral fluid. Ann Clin Biochem. 2005;42:277–84. [PubMed] [Google Scholar]
80. Gunnar T, Ariniemi K, Lillsunde P. Validated toxicological determination of 30 drugs of abuse as optimized derivatives in oral fluid by long column fast gas chromatography/electron impact mass spectrometry. J Mass Spectrom. 2005;40:739–53. [PubMed] [Google Scholar]
81. Wylie FM, Torrance H, Anderson RA, Oliver JS. Drugs in oral fluid Part I. Validation of an analytical procedure for licit and illicit drugs in oral fluid. Forensic Sci Int. 2005;150:191–8. [PubMed] [Google Scholar]
82. Mortier KA, Maudens KE, Lambert WE, et al. Simultaneous, quantitative determination of opiates, amphetamines, cocaine and benzoylecgonine in oral fluid by liquid chromatography quadrupole-timeof- flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;779:321–30. [PubMed] [Google Scholar]
83. Wood M, Laloup M, Ramirez Fernandez Mdel M, et al. Quantitative analysis of multiple illicit drugs in preserved oral fluid by solid-phase extraction and liquid Clin Biochem Rev Vol 27 August 2006 I 157 Oral Fluid Drugs chromatography-tandem mass spectrometry. Forensic Sci Int. 2005;150:227–38. [PubMed] [Google Scholar]
84. Dams R, Murphy CM, Choo RE, Lambert WE, De Leenheer AP, Huestis MA. LC-atmospheric pressure chemical ionization-MS/MS analysis of multiple illicit drugs, methadone, and their metabolites in oral fluid following protein precipitation. Anal Chem. 2003;75:798–804. [PubMed] [Google Scholar]
85. Draft Standard: Procedures for the collection, detection and quantitation of drugs in oral fluid. Standards Australia, 2006.
86. Niedbala R, Kardos K, Salamone S, Fritch D, Bronsgeest M, Cone EJ. Passive cannabis smoke exposure and oral fluid testing. J Anal Toxicol. 2004;28:546–52. [PubMed] [Google Scholar]
87. Rohrig TP, Moore C. The determination of morphine in urine and oral fluid following ingestion of poppy seeds. J Anal Toxicol. 2003;27:449–52. [PubMed] [Google Scholar]
88. Maurer HH. Advances in analytical toxicology: the current role of liquid chromatography-mass spectrometry in drug quantification in blood and oral fluid. Anal Bioanal Chem. 2005;381:110–8. [PubMed] [Google Scholar]
89. National Association of Testing Authorities, see www.nata.asn.au (accessed March 27, 2006).
90. de la Torre R, Segura J, de Zeeuw R, Williams J. Recommendations for the reliable detection of illicit drugs in urine in the European Union, with special attention to the workplace. EU Toxicology Experts working Group. Ann Clin Biochem 1997;34:339–44.. [PubMed]
91. Peters FT, Maurer HH. Bioanalytical method validation and its implications for forensic and clinical toxicology - A review. Accred Qual. Assur. 2002;7:441–9. [Google Scholar]
92. Clarke J, Wilson JF. Proficiency testing (external quality assessment) of drug detection in oral fluid. Forensic Sci Int. 2005;150:161–4. [PubMed] [Google Scholar]
93. Walsh JM, Flegel R, Crouch DJ, Cangianelli L, Baudys J. An evaluation of rapid point-of-collection oral fluid drug-testing devices. J Anal Toxicol. 2003;27:429–39. [PubMed] [Google Scholar]
94. Crouch DJ, Walsh JM, Flegel R, Cangianelli L, Baudys J, Atkins R. An evaluation of selected oral fluid point-of- collection drug-testing devices. J Anal Toxicol. 2005;29:244–8. [PubMed] [Google Scholar]
95. Cooper G, Wilson L, Reid C, Main L, Hand C. Evaluation of the Cozart((R)) RapiScan drug test system for opiates and cocaine in oral fluid. Forensic Sci Int. 2005;150:239– 43. [PubMed] [Google Scholar]
96. Moore L, Wicks J, Spiehler V, Holgate R. Gas chromatography-mass spectrometry confirmation of Cozart RapiScan saliva methadone and opiates tests. J Anal Toxicol. 2001;25:520–4. [PubMed] [Google Scholar]
97. Toennes SW, Kauert GF, Steinmeyer S, Moeller MR. Driving under the influence of drugs -- evaluation of analytical data of drugs in oral fluid, serum and urine, and correlation with impairment symptoms. Forensic Sci Int. 2005;152:149–55. [PubMed] [Google Scholar]
98. Kintz P, Bernhard W, Villain M, Gasser M, Aebi B, Cirimele V. Detection of cannabis use in drivers with the drugwipe device and by GC-MS after Intercept device collection. J Anal Toxicol. 2005;29:724–7. [PubMed] [Google Scholar]
99. Cone EJ, Presley L, Lehrer M, et al. Oral fluid testing for drugs of abuse: positive prevalence rates by Intercept immunoassay screening and GC-MS-MS confirmation and suggested cutoff concentrations. J Anal Toxicol. 2002;26:541–6. [PubMed] [Google Scholar]
100. Kintz P, Villain M, Concheiro M, Cirimele V. Screening and confirmatory method for benzodiazepines and hypnotics in oral fluid by LC-MS/MS. Forensic Sci Int. 2005;150:213–20. [PubMed] [Google Scholar]
101. Barrett C, Good C, Moore C. Comparison of point-of- collection screening of drugs of abuse in oral fluid with a laboratory-based urine screen. Forensic Sci Int. 2001;122:163–6. [PubMed] [Google Scholar]
102. Cirimele V, Villain M, Mura P, Bernard M, Kintz P. Oral fluid testing for cannabis: On-site Oraline(R) IV s.a.t. device versus GC/MS. Forensic Sci Int 2006; July 17; [Epub ahead of print] [PubMed]
103. Lamey PJ, Nolan A. The recovery of human saliva using the Salivette system. Eur J Clin Chem Clin Biochem. 1994;32:727–8. [PubMed] [Google Scholar]
104. Biermann T, Schwarze B, Zedler B, Betz P. On-site testing of illicit drugs: the use of the drug-testing device "Toxiquick". Forensic Sci Int. 2004;143:21–5. [PubMed] [Google Scholar]
105. Cone EJ. Saliva testing for drugs of abuse. Ann N Y Acad Sci. 1993;694:91–127. [PubMed] [Google Scholar]
106. Inaba T, Kalow W. Salivary excretion of amobarbital in man. Clin Pharmacol Ther. 1975;18:558–62. [PubMed] [Google Scholar]
107. van der Graaff M, Vermeulen NP, Heij P, Boeijinga JK, Breimer DD. Pharmaco*kinetics of orally administered hexobarbital in plasma and saliva of healthy subjects. Biopharm Drug Dispos. 1986;7:265–72. [PubMed] [Google Scholar]
108. Navarro M, Pichini S, Farre M, et al. Usefulness of saliva for measurement of 3,4-methylenedioxymetham phetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. Clin Chem. 2001;47:1788–95. [PubMed] [Google Scholar]
109. Chikhi-Chor N, Pham-Huy C, Galons H, et al. Rapid determination of methadone and its major metabolite in biological fluid s by gas-liquid chromatography with thermionic detection for maintenance treatment of opiate addicts. J Chromatogr B Biomed Sci Appl. 1998;718:278–84. [PubMed] [Google Scholar]
110. Kankaanpaa A, Gunnar T, Ariniemi K, Lillsunde P, Mykkanen S, Seppala T. Single-step procedure for gas chromatography-mass spectrometry screening and quantitative determination of amphetamine-type stimulants and related drugs in blood, serum, oral fluid and urine samples. J Chromatogr B Analyt Technol Biomed Life Sci 2004;810:57–68. 158 I Clin Biochem Rev Vol 27 August 2006 Drummer O [PubMed]
111. Wood M, De Boeck G, Samyn N, et al. Development of a rapid and sensitive method for the quantitation of amphetamines in human plasma and oral fluid by LCMS- MS. J Anal Toxicol. 2003;27:78–87. [PubMed] [Google Scholar]
112. Quintela O, Cruz A, Castro A, Concheiro M, Lopez- Rivadulla M. Liquid chromatography-electrospray ionisation mass spectrometry for the determination of nine selected benzodiazepines in human plasma and oral fluid. Journal of Chromatography B Analyt Technol Biomed Life Sci. 2005;825:63–71. [PubMed] [Google Scholar]
